<?xml version="1.0" encoding="UTF-8"?>
<p>The clinical implementation of NAC has facilitated breast-conserving surgery (lumpectomy) and sentinel lymph node biopsy for women who historically would require mastectomy and axillary lymph node dissection.
 <sup>
  <xref rid="zoi201035r2" ref-type="bibr">2</xref>,
  <xref rid="zoi201035r3" ref-type="bibr">3</xref>
 </sup> The optimal outcome after NAC is a pathologic complete response (pCR), which is defined as no remaining invasive or in situ cancer in the breast. A pCR is a surrogate end point that is a marker for improved disease-free and overall survival.
 <sup>
  <xref rid="zoi201035r4" ref-type="bibr">4</xref>,
  <xref rid="zoi201035r6" ref-type="bibr">6</xref>
 </sup> The likelihood of achieving pCR is largely based on breast cancer subtype (clinically defined by immunohistochemical surrogates of estrogen receptor, progesterone receptor, and 
 <italic>ERBB2</italic> (formerly 
 <italic>HER2</italic> or 
 <italic>HER2</italic>/neu) amplification, with 
 <italic>ERBB2</italic>-positive and triple-negative subtypes having the highest likelihood of pCR of up to 66.2%
 <sup>
  <xref rid="zoi201035r7" ref-type="bibr">7</xref>
 </sup> and 37%,
 <sup>
  <xref rid="zoi201035r8" ref-type="bibr">8</xref>
 </sup> respectively.
</p>
